Haemonetics is trading at $114.33, up 12.41%, after CSL said it expects to complete rollout of NexSys PCS devices and related disposables across all current U.S. plasma collection centers by the end of 2027. - CNBC explicitly linked the premarket move to the rollout update. - The update is under a non-exclusive supply agreement; an earlier filing said there were no minimum purchase commitments. - The broader market was softer at the time; intraday volume data was unavailable.